Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. (4th March 2018)

• Record Type: Journal Article
• Authors: Amin, Alpesh; Keshishian, Allison; Vo, Lien; Zhang, Qisu; Dina, Oluwaseyi; Patel, Chad; Odell, Kevin; Trocio, Jeffrey
• Is Part Of: Journal of medical economics. Volume 21:Number 3(2018)
• Page Start: 244
• Page End: 253
• Publication Date: 2018-03-04
• Subjects: Cardiac arrhythmias -- anticoagulants -- major bleeding -- stroke -- costs -- cost analysis; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2017.1394866
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Aims: To compare the risk of all-cause hospitalization and hospitalizations due to stroke/systemic embolism (SE) and major bleeding, as well as associated healthcare costs for non-valvular atrial fibrillation (NVAF) patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. Materials and methods: NVAF patients initiating apixaban, dabigatran, rivaroxaban, or warfarin were selected from the OptumInsight Research Database from January 1, 2013–September 30, 2015. Propensity score matching (PSM) was performed between apixaban and each oral anticoagulant. Cox models were used to estimate the risk of stroke/SE and major bleeding. Generalized linear and 2-part models were used to compare healthcare costs. Results: Of the 47, 634 eligible patients, 8, 328 warfarin-apixaban pairs, 3, 557 dabigatran-apixaban pairs, and 8, 440 rivaroxaban-apixaban pairs were matched. Compared to apixaban, warfarin patients were associated with a significantly higher risk of all-cause (hazard ratio [HR] = 1.30; 95% confidence interval [CI] = 1.21–1.40) as well as stroke/SE-related (HR = 1.60; 95% CI = 1.23–2.07) and major bleeding-related (HR = 1.95; 95% CI = 1.60–2.39) hospitalization; rivaroxaban patients were associated with a higher risk of all-cause (HR = 1.15; 95% CI = 1.07–1.24) and major bleeding-related hospitalization (HR = 1.71; 95% CI = 1.39–2.10); and dabigatran patients were associated with a higher risk of major bleeding hospitalization (HR = 1.46, 95% CI = 1.02–2.10). Warfarin patients had significantly higher major bleeding-related and total all-cause healthcare costs compared to apixaban patients. Rivaroxaban patients had significantly higher major bleeding-related costs compared to apixaban patients. No significant results were found for the remaining comparisons. Limitations: No causal relationships can be concluded, and unobserved confounders may exist in this retrospective database analysis. Conclusions: This study demonstrated a significantly higher risk of hospitalization (all-cause, stroke/SE, and major bleeding) associated with warfarin, a significantly higher risk of major bleeding hospitalization associated with dabigatran or rivaroxaban, and a significantly higher risk of all-cause hospitalization associated with rivaroxaban compared to apixaban. Lower major bleeding-related costs were observed for apixaban patients compared to warfarin and rivaroxaban patients.